

11. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. *J Am Coll Cardiol*. 2011; 58(13): 1378–1385.
12. Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. *Eur Urol*. 2014; 65(5): 968–978.
13. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. *N Engl J Med*. 1998; 338(20): 1397–1404.
14. Moncada I, Jara J, Subirá D, Castaño I, Hernández C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. *Eur Urol*. 2004; 46(3): 357–361.
15. Curran M, Keating G. Tadalafil. *Drugs*. 2003; 63(20): 2203–2214.
16. Ventimiglia E, Capogrosso P, Montorsi F, Salonia A. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. *Expert Opin Drug Saf*. 2016; 15(2): 141–152.
17. Keating GM, Scott LJ. Vardenafil: a review of its use in erectile dysfunction. *Drugs*. 2003; 63(23): 2673–2703.
18. Capogrosso P, Ventimiglia E, Boeri L, et al. Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials. *Expert Rev Clin Pharmacol*. 2017; 10(3): 339–344.
19. Chung E, Broc GB. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. *Expert Opin Pharmacother*. 2011; 12(8): 1341–1348.
20. Wang R, Burnett AL, Heller WH, et al. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. *J Sex Med*. 2012; 9(8): 2122–2129.
21. Goldstein I, McCullough AR, Jones LA, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. *J Sex Med*. 2012; 9(4): 1122–1133.
22. Corona G, Rastrelli G, Burri A, Jannini EA, Maggi M. The safety and efficacy of Avanafil, a new 2nd generation PDE5i: comprehensive review and meta-analysis. *Expert Opin Drug Saf*. 2016; 15(2): 237–247.
23. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. *Urology*. 2002; 60(2 Suppl 2): 28–38.
24. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. *J Clin Pharmacol*. 2003; 43(3): 260–267.
25. Forgue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. *Br J Clin Pharmacol*. 2006; 61(3): 280–288.
26. Swearingen D, Nehra A, Morelos S, Peterson CA. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. *Drugs Context*. 2013; 2013: 212248.
27. Gur S, Kadowitz PJ, Gokce A, et al. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension. *Curr Drug Metab*. 2013; 14(2): 265–269.
28. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. *J Endocrinol Invest*. 2008; 31(9): 799–808.
29. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. *Clin Cardiol*. 2004; 27(4 Suppl 1): I20–I25.
30. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. *Mayo Clin Proc*. 2012; 87(8): 766–778.
31. Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. *Am J Hypertens*. 2004; 17(12 Pt 1): 1135–1142.
32. Satake N, Zhou Q, Morikawa M, Inoue M, Shibata S. Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoproterenol in isolated rat aorta: involvement of cyclic GMP-inhibitable cyclic AMP phosphodiesterase. *J Cardiovasc Pharmacol*. 1995; 25(3): 489–494.